Follow-up study for adults who received EBT-101 for HIV
Part of Infections clinical trials.
This study checks how adults are doing long-term after receiving an HIV treatment called EBT-101 in an earlier study. It helps researchers understand safety and longer-term effects over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able and willing to sign written informed consent
- You must have received EBT-101 in the earlier (parent) study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This study looks at how the immune system and HIV behave in people on long-term HIV treatment (ART), using blood samples that will be stored for future tests for up to 20 years. It may help researchers understand how well treatment is controlling HIV and improve future care.
This study looks at long-term outcomes for people with recessive dystrophic epidermolysis bullosa (RDEB) who were previously treated with EB-101. It may help doctors understand how the treatment affects patients over time.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
This study is for people who have already received BEAM-101 in a previous study. It simply follows them over time to track their health and any long-term effects.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.